NEJM shared on X:
“Presented at WCLC26:
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher.
Full phase 3 TAISHAN-302 trial results.
Title: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Authors: Yuanyuan Zhao, Hongxu Liu, Xiangjiao Meng, Zhihua Liu, Yan Yu, Yulong Zheng, Longhua Sun
Vera Ghali, Medical Doctor Pediatrics, Allergy and Immunology, Member of the Lebanese Order of Physicians and Lebanese Pediatric Society, shared NEJM’s post, adding:
“Promising results from phase 3 TAISHAN-302 trial for the treatment of patients with Small Cell Lung Cancer (SCLC) with relapsed extensive-stage progression after initial treatment with first-line platinum-based chemotherapy.
Results of the early-phase trial showed that tambotatug pelitecan (Tam-Peli), an investigational, next-generation antibody-drug conjugate (ADC) targeting B7-H3 (CD 276), an immune-checkpoint molecule that is highly expressed in solid tumors, resulted in longer survival and longer progression-free survival than patients receiving topotecan, a cytotoxic, topoisomirase I inhibitor that stops cancer cells from repairing and replicating DNA leading to cell death and is considered as the standard second-line chemotherapy for SCLC.
Treatment with tam-peli also showed a lower incidence of adverse events (AEs) of grade 3 or higher.
Hopefully, this new treatment will improve survival and quality of life for patients with SCLC.”
Other articles about NEJM on OncoDaily.
